Melanoma: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Lisa Kottschade, APRN, MSN, CNP
J Adv Pract Oncol 2020;11(6):609-611 |
© 2020 Harborside™
With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews clinical data on which patients with metastatic melanoma should receive combination therapy vs. single-agent PD-1 up front, and what to do at the time of progression on PD-1 monotherapy.
For access to the full length article, please sign in